Camp, Chad R. http://orcid.org/0000-0002-3415-4652
Vlachos, Anna http://orcid.org/0000-0002-4411-9447
Klöckner, Chiara
Krey, Ilona
Banke, Tue G.
Shariatzadeh, Nima
Ruggiero, Sarah M.
Galer, Peter
Park, Kristen L. http://orcid.org/0000-0001-5527-3047
Caccavano, Adam
Kimmel, Sarah
Yuan, Xiaoqing
Yuan, Hongjie http://orcid.org/0000-0002-8127-7145
Helbig, Ingo
Benke, Tim A.
Lemke, Johannes R. http://orcid.org/0000-0002-4435-6610
Pelkey, Kenneth A. http://orcid.org/0000-0002-9731-1336
McBain, Chris J. http://orcid.org/0000-0002-5909-0157
Traynelis, Stephen F. http://orcid.org/0000-0002-3750-9615
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS111619, NS113530, MH127404, HD082373, K02NS112600, U24NS120854-01, U54NS108874-04)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Article History
Received: 23 March 2023
Accepted: 29 August 2023
First Online: 19 September 2023
Competing interests
: H.Y. and S.F.T. are co-inventors of Emory-owned intellectual property. S.F.T. is a member of the SAB for Sage Therapeutics, Eumentis Therapeutics, the GRIN2B Foundation, the CureGRIN Foundation, and CombinedBrain. S.F.T. is a consultant for GRIN Therapeutics and Neurocrine. H.Y. is the PI on a research grant from Sage Therapeutics to Emory. S.F.T. is cofounder of NeurOp, Inc. and Agrithera. T.A.B. is a member of the SAB for GRIN2B Foundation, CureGRIN Foundation, GRIN Therapeutics, and Neurocrine; all remuneration has been made to his department. T.G.B. is PI on a research grant from Neumora to Emory University. J.R.L. is a consultant for GRIN Therapeutics and a member of the SAB for GRIN2B Foundation and CureGRIN Foundation. All other authors declare no competing interests.